Bioluminescence technology pioneered at The University of Western Australia has been used to uncover a potential game-changer in immunotherapy. The results of the study led by researchers at UWA and the University of Nottingham in the U.K. Dr. Carl White said CXCL17 is a potent inhibitor of the CXCR4 chemokine receptor.